ArticleOncotarget2017
Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Advances in the Detection of Pancreatic Cancer Through Liquid Biopsy.Frontiers in oncology · 2021Pooled it
- Prognostic value of circulating tumor DNA in pancreatic cancer: a systematic review and meta-analysis.Aging · 2020Pooled it
- Clinical Utility of Circulating Tumor DNA Analysis in Pancreatic Ductal Adenocarcinoma.Clinical Medicine Insights. Oncology · 2026Article
- Circulating tumour DNA (ctDNA) as a predictor of progression-free and overall survival in non-resectable pancreatic cancer: a systematic review and meta-analysis.The journal of liquid biopsy · 2025Review
- Assessment of cancer biomarkers in the Grenfell firefighter cohort study.Scientific reports · 2025Article
- Identification of ordinal relations and alternative suborders within high-dimensional molecular data.Frontiers in bioinformatics · 2025Article
- Building on the clinical applicability of ctDNA analysis in non-metastatic pancreatic ductal adenocarcinoma.Scientific reports · 2024Article
- Clinical Application of Liquid Biopsy in Pancreatic Cancer: A Narrative Review.International journal of molecular sciences · 2024Review
- Understanding and Overcoming Immunosuppression Shaped by Cancer Stem Cells.Cancer research · 2023Article
- Review
- Circulating tumor DNA: toward evolving the clinical paradigm of pancreatic ductal adenocarcinoma.Therapeutic advances in medical oncology · 2023Review
- Review
- Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.BMC cancer · 2022Article
- Evaluating Pancreatic and Biliary Neoplasms with Small Biopsy-Based Next Generation Sequencing (NGS): Doing More with Less.Cancers · 2022Review
- Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives.Cancers · 2021Review
- Meta-Analysis of Circulating Cell-Free DNA's Role in the Prognosis of Pancreatic Cancer.Cancers · 2021Review
- Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma.The oncologist · 2021Article
- Molecular profiling of ctDNA in pancreatic cancer: Opportunities and challenges for clinical application.Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2021Review
- Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review.Cancers · 2021Review
- Bead-Based Isolation of Circulating Tumor DNA from Pancreatic Cancer Patients Enables High Fidelity Next Generation Sequencing.Cancer management and research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 1 country.
Funding
Abstract
The majority of pancreatic ductal adenocarcinomas (PDAC) are diagnosed late so that surgery is rarely curative. Earlier detection could significantly increase the likelihood of successful treatment and improve survival. The aim of the study was to provide proof of principle that point mutations in key cancer genes can be identified by sequencing circulating free DNA (cfDNA) and that this could be used to detect early PDACs and potentially, premalignant lesions, to help target early effective treatment. Targeted next generation sequencing (tNGS) analysis of mutation hotspots in 50 cancer genes was conducted in 26 patients with PDAC, 14 patients with chronic pancreatitis (CP) and 12 healthy controls with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.